Surrogate endpoints: the debate goes on

被引：7

作者：

Ellenberg, SS ^{[1
]}

机构：

[1] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2001年 / 10卷 / 06期

关键词：

D O I：

10.1002/pds.655

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：493 / 496

页数：4

共 29 条

[1]

Albert JM, 1998, STAT MED, V17, P2435, DOI 10.1002/(SICI)1097-0258(19981115)17:21&lt

[2]

2435::AID-SIM994&gt

[3]

3.3.CO

[4]

2-7

[5]

Alderman M, 1997, J HYPERTENS, V15, P105

[6] A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure [J].

Cohn, JN ;

Goldstein, SO ;

Greenberg, BH ;

Lorell, BH ;

Bourge, RC ;

Jaski, BE ;

Gottlieb, SO ;

McGrew, F ;

DeMets, DL ;

White, BG .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25) :1810-1816

[7] BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].

COLLINS, R ;

MACMAHON, S .

BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298

[8]

Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.3.CO

[9]

2-D

[10] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].

Davis, BR ;

Cutler, JA ;

Gordon, DJ ;

Furberg, CD ;

Wright, JT ;

Cushman, WC ;

Grimm, RH ;

LaRosa, J ;

Whelton, PK ;

Perry, HM ;

Alderman, MH ;

Ford, CE ;

Oparil, S ;

Francis, C ;

Proschan, M ;

Pressel, S ;

Black, HR ;

Hawkins, CM .

AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360

← 1 2 3 →